Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (tysabri®) Dosing: NOVA Phase IIIb Extension Study (part 2)
Neurology and Therapy（2024）
Key words
Extended interval dosing,Intravenous,Multiple sclerosis,Natalizumab,NOVA,Patient preference,Subcutaneous
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined